

DESCRIPTION


Species Reactivity	Human
Specificity	Stains human KIR2DL4/CD158d transfected BaF/3 cells. It does not recognize transfectants that express KIR2DL1, 2DL2, 2DL3, 2DL5, 2DS1, 2DS2, 2DS4, 3DL1, 3DL2, or 3DS1.
Source	Monoclonal Mouse IgG _{2A} Clone # 181703
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	BaF3 mouse pro-B cell line transfected with human KIR2DL4/CD158d Accession # Q99706
Endotoxin Level	<0.10 EU per 1 µg of the antibody by the LAL method.
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
Agonist Activity	0.5-2 µg/mL	See Below
Flow Cytometry	2.5 µg/10 ⁶ cells	NK92 human natural killer lymphoma cell line
CytoF-reported	Horowitz, A. <i>et al.</i> Sci. Transl. Med. (2013) 208ra145. Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	

DATA



PREPARATION AND STORAGE

Reconstitution	Reconstitute at 0.5 mg/mL in sterile PBS.
Shipping	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. <ul style="list-style-type: none"> ● 12 months from date of receipt, -20 to -70 °C as supplied. ● 1 month, 2 to 8 °C under sterile conditions after reconstitution. ● 6 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

KIR2DL4 (also known as 2DL4, p49, CD158d, KIR103) is a type I transmembrane protein of the killer cell Ig-like receptor (KIR) family expressed on NK and subsets of $\gamma\delta$ T and memory/effector $\alpha\beta$ T cells. KIR2DL4 is a unique KIR (1-3); alleles are not clonally restricted but are expressed codominantly (4) in all activated NK cells and constitutively on CD56^{hi} NK cells. KIR members with two Ig-like domains (2D) usually express domains D1 and D2, but KIR2DL4 expresses D0 and D2. Other long-tailed (L) KIR have two cytoplasmic inhibitory signaling domains (ITIM), but KIR2DL4 has one ITIM and also exhibits characteristics of activating KIR (2). An arginine within the transmembrane sequence of KIR2DL4 interacts with the signaling molecule Fc ϵ R1- γ , while in activating KIR, a transmembrane lysine interacts with DAP12 (1, 5). The KIR2DL4 gene is highly polymorphic. Seven splice variants missing one or more exons have been identified, but it is not clear whether these are expressed. Several of the nine alleles identified encode a frameshift creating a prematurely truncated protein. It is estimated that up to 25% of humans do not express KIR2DL4 capable of reaching the cell surface (1, 7, 10). Human KIR2DL4 is 65-83% amino acid identical to other primates. KIR receptors have no structural orthologs in non-primates, although mouse Ly49 proteins are functional orthologs. Cross-linking of KIR2DL4 induces NK cells to produce IFN- γ (6, 7); stimulation with IL-2 upregulates cell surface expression on CD56^{dim} cells and allows cytotoxicity (7). Although a role in immune privilege of the fetus has been suggested due to reported recognition of fetal trophoblast HLA-G by KIR2DL4 in the maternal decidua (11), subsequent data have not supported this recognition (1, 9).

References:

1. Lanier, L.L. (2005) *Annu. Rev. Immunol.* **23**:225.
2. Faure, M. and E.O. Long (2002) *J. Immunol.* **168**:6208.
3. Selvakumar, A. *et al.* (1996) *Tissue Antigens* **48**:285.
4. Chan, H-W. *et al.* (2003) *J. Exp. Med.* **197**:245.
5. Kikuchi-Maki, A. *et al.* (2005) *J. Immunol.* **174**:3859.
6. Rajagopalan, S. *et al.* (2001) *J. Immunol.* **167**:1877.
7. Kikuchi-Maki, A. *et al.* (2003) *J. Immunol.* **171**:3415.
8. Gedil, M.A. *et al.* (2005) *Tissue Antigens* **65**:402.
9. Witt, C.S. *et al.* (2002) *Eur. J. Immunol.* **32**:18.
10. Goodridge, J.P. *et al.* (2003) *J. Immunol.* **171**:1768.
11. Ponte, M. *et al.* (1999) *Proc. Natl. Acad. Sci. USA* **96**:5674.